Publicaciones en colaboración con investigadores/as de University of Toronto (21)

2023

  1. A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

    Science translational medicine, Vol. 15, Núm. 697, pp. eadf4549

  2. Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses

    Cell Reports, Vol. 42, Núm. 4

2022

  1. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 7

  2. Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 4

2021

  1. Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile

    iScience, Vol. 24, Núm. 9

  2. Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice

    Science Advances, Vol. 7, Núm. 49

  3. Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

    Scientific Reports, Vol. 11, Núm. 1

  4. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments

    Cell Reports, Vol. 32, Núm. 7

  2. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease

    Science Translational Medicine, Vol. 10, Núm. 423

2017

  1. Diverse Applications of Nanomedicine

    ACS Nano, Vol. 11, Núm. 3, pp. 2313-2381

2015

  1. Phosphorylation-dependent changes in nucleotide binding, conformation, and dynamics of the first nucleotide binding domain (NBD1) of the sulfonylurea receptor 2B (SUR2B)

    Journal of Biological Chemistry, Vol. 290, Núm. 37, pp. 22699-22714

2014

  1. Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: Implications for antibody recognition mechanism and immunogen design

    Journal of Biological Chemistry, Vol. 289, Núm. 10, pp. 6565-6580

2012

  1. NMR and fluorescence studies of drug binding to the first nucleotide binding domain of SUR2A

    Biochemistry, Vol. 51, Núm. 45, pp. 9211-9222

2011

  1. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization

    AIDS Research and Human Retroviruses, Vol. 27, Núm. 8, pp. 863-876

2010

  1. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding

    Journal of Virology, Vol. 84, Núm. 9, pp. 4136-4147

  2. Putative one-pot prebiotic polypeptides with ribonucleolytic activity

    Chemistry - A European Journal, Vol. 16, Núm. 18, pp. 5314-5323

2009

  1. Structural Constraints Imposed by the Conserved Fusion Peptide on the HIV-1 gp41 Epitope Recognized by the Broadly Neutralizing Antibody 2F5

    Journal of Physical Chemistry B, Vol. 113, Núm. 41, pp. 13626-13637